drugset / Trial / NCT04626765
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
Phase 0
Unknown
50 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, CAR-T will be administered to children with acute lymphoblastic leukemia to explore the effect of CAR-T intervention time on the duration of complete remission and further verify the long-term safety and efficacy of CAR-T treatment.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2023-03-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | — | — |
| Subject | CD19+22 | Cell therapy | — | — |
| Subject | CD22 CAR-T | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |